中西医结合诊治多囊卵巢综合征（PCOS）不孕症临床研究
|
摘要
[研究目的]
本研究是在辨病、辨证的基础上,把PCOSⅠ型(非肥胖型)辩证为肾虚血瘀；PCOSⅡ型(肥胖型)辨证为脾虚血瘀,应用导师2个经验方即PCOSⅠ号方和PCOS2号方分别对PCOS2型即PCOSⅠ型(非肥胖型)合PCOSⅡ型(肥胖型)进行治疗,探讨2方对PCOS2型的临床症状、内分泌激素、排卵率、妊娠率、总疗效的作用,以指导临床治疗PCOS所致不孕症最佳治疗方案,并为临床中成药的开发提供临床基础。
[研究方法]
根据文献研究和导师经验把PCOS所致不孕症按非肥胖和肥胖分为2型,在CC促排卵的基础上分别配合PCOS1号方治疗PCOSⅠ型；以PCOS2号方治疗PCOSⅡ型。
PCOSⅠ型(非肥胖型)临床研究：纳入病例标准符合PCOSⅠ型诊断标准及肾虚血瘀辨证标准,年龄在25岁至35岁已婚患者60例。按随机分配的原则分治疗组(中西结合组),对照组(西药组)各30例。
中西结合组(治疗组)：与月经或孕酮撤退性出血第1天测基础体温,第5天起应用克罗米芬胶囊(CC),每日一次,每次50mg口服,连用5天；同时加用PCOS1号方(即导师尤昭玲教授经验方)口服；对照组单用CC治疗。治疗组和对照组皆治疗3个月经周期为一疗程,用1个疗程,进行疗效统计。观察PCOS1号方对PCOSⅠ型的临床症状、内分泌激素、排卵率、妊娠率、总疗效的作用
PCOSⅡ型(肥胖型)临床研究：纳入病例标准符合PCOSⅡ型诊断标准及脾虚血瘀辨证标准,年龄在25岁至35岁已婚患者60例。按随机分配的原则分治疗组(中西结合组),对照组(西药组)各30例。治疗组与月经或孕酮撤退性出血第1天测基础体温,第5天起应用克罗米芬胶囊(CC),每日一次,每次50mg口服,连用5天；同时加用PCOS2号方(即导师尤昭玲教授经验方)口服,余下治疗和观察同PCOSⅠ型(非肥胖型)临床研究。
[结果]
1 PCOSⅠ型所致不孕证临床研究结果：
(1)治疗组妊娠率63.%,总有效率为90%；对照组妊娠率46.7%,总有效率为73.3%。两组比较,P<0.05,差异有显著性意义。
(2)两组治疗后比较,治疗组在改善月经周期、腰骶酸痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡方面优于对照组,经统计学处理,差异有显著性(P<0.05),治疗组中医证候总有效率为63.3%,对照组为33.3%,两组差异有显著性(P<0.05),
(3)血内分泌水平变化治疗组治疗前后比较内分泌激素有显著性变化(P<0.05),T、LH明显下降,E2升高。对照组治疗前后生殖内分泌激素虽稍有变化,但无统计学意义P>0.05
(4)两组周期排卵率比较,治疗组周期排卵率63.5%,对照组周期排卵率28.4%,两组周期排卵率比较有统计学意义(P<0.01)
2 PCOSⅡ型(肥胖型)临床研究结果
(1)临床疗效观察：治疗组妊娠率46.7%,总有效率为76.7%；对照组妊娠率23.3%,总有效率为46.7%。两组进行统计学检验,P<0.05差异有显著性意义。
(2)临床表现与中医证候治疗前后比较两组治疗后比较,治疗组在改善月经周期、腰骶酸痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡方面优于对照组,经统计学处理,差异有显著性(P<0.05)。治疗组中医证候总有效率为63.3%,对照组为33.3%,两组差异有显著性(P<0.05),
(3)血内分泌水平变化治疗组治疗前后比较内分泌激素有显著性变化(P<0.05),T、INS明显下降。对照组治疗前后生殖内分泌激素虽稍有变化,但无统计学意义P>0.05,
(4)两组周期排卵率比较治疗组周期排卵率39.5%,对照组周期排卵率19.0%,两组比较有统计学意义(P<0.01)。
[结论]
1. PCOSⅠ号方干预可提高PCOSⅠ型总疗效,并能有效提高妊娠率,达到调经助孕的目的。
2. PCOSⅠ号方可明显改善PCOSⅠ型中月经周期异常、月经色、量异常、经行小腹胀痛、头晕、腰骶酸痛、粉刺、口干症状。对舌脉也有明显改善作用。对多毛症状无改善,可能与疗程短有关。
3. PCOSⅠ号方能使非肥胖型PCOSⅠ型患者血清内分泌T、LH明显下降,E2升高,LH/FSH比值较治疗前降低,说明PCOSⅠ号方能改善卵巢功能,能调节下丘脑—垂体—卵巢轴的功能,纠正紊乱的内分泌环境。
4. PCOSⅠ号方对非肥胖型PCOSⅠ型可提高排卵率,有促排卵作用。
5. PCOSⅡ号方可提高肥胖型PCOSⅡ号总疗效,并能有效提高其妊娠率,但与PCOSⅠ型治疗妊娠率比较,PCOSⅡ型妊娠率明显低于PCOSⅠ型。
6. PCOSⅡ号方干预PCOSⅡ型可明显改善月经周期异常、月经色、量异常、经行小腹胀痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡、腰骶酸痛等临床表现。但对肥胖稍有改善,这可能与疗程短有关。
7. PCOSⅡ号方通过降低PCOSⅡ型胰岛素水平,改善外周胰岛素抵抗状态,调节糖、脂代谢以改善PCOS患者的卵巢局部异常的内分泌状态,降低雄激素水平,使排卵功能恢复,排卵率增加,改善生殖机能。
8. PCOSⅡ型比较PCOSⅠ型妊娠率较低,单用CC治疗PCOSⅡ型妊娠率更低,可能与肥胖可加剧高胰岛素血症,导致过多的雄激素产生,使PCOS内分泌更为复杂
综上所述,本研究在辨证施治的基础上辨病论治,以不同的方药对PCOS分型进行论治。中药可调节PCOS患者失调的内环境,促使其生殖功能的恢复。
Object:Polycystic ovary syndrome is a kind of endocrine disease that with different causes and polymorphism clinical manifestation. Moreover, PCOS is also a main reason that causes infertility because of not having ovary sends.
The thesis intends to divide the PCOSⅠinto kidney efficiency and blood stasis and PCOSⅡinto spleen efficiency and blood stasis, on the basis of the researches of diseases and actual examples. Moreover, the author also intends to adopt her tutor's two excellent experiences-PCOSⅠmethod and PCOSⅡmethod to have a thorough study on PCOS 2, thus exploring the influence of the two methods on PCOS 2, including its clinical manifestations, inner incretion hormone, the ovary sends'rate, the pregnancy rate and the general effect, and instructing a clinical basis on the development of Chinese medicine.
Methods:The author has not only divided the infertility caused by PCOS into obese and non-obese, on the basis of the established researches and the author's actual experience, but also has adopted the corresponding way of PCOS 1 to cure PCOSⅠand PCOS 2 for PCOSⅠon the basis of the research of CC, which helps to speed up the ovary sends.
Clinical research of PCOSⅠ(Non-obese):A Case standards into line with PCOSⅠdiagnostic standard and kidney deficiency and blood stasis dialectical standard, the age of 25-year-old to 35-year-old married in 60 cases. According to the random distribution principle, it is divided into the treatment group (combination of Chinese and Western group) and the contrastive group (WM group) of the 30 cases.
Treatment group and menstruation or progesterone withdrawal bleeding:have a temperature measurement basis at the first day, take the medicine clomiphene capsules (CC) after five days, once daily,50 mg orally each day for five days at the same time, plus the PCOS2 (i.e. the author's tutor Professor You Zhaoling's experience), oral. Treatment group and the control group were three of the menstrual cycle for treatment with a course of treatment and an efficient statistics. The observation side PCOS1 method plays a role in the clinical symptoms, endocrine hormone, ovulation rate, pregnancy rate and the total effect of PCOSⅠ
PCOSⅡtype (obese) Clinical Research:A Case standards into line with PCOSⅡdiagnostic criteria and spleen deficiency and blood stasis standards, the age of 25-year-old to 35-year-old married in 60 cases. According to the random distribution principle, it is divided into the treatment group (combination of Chinese and Western), the control group (WM group) of the 30 cases. Treatment group and menstruation or progesterone withdrawal bleeding:have a temperature measurement basis at the first day, take the medicine clomiphene capsules (CC) after five days, once daily,50 mg orally each day for five days at the same time, plus the PCOS2 (i.e. the author's tutor Professor You Zhaoling's experience), oral, and the remaining treatment and observation has the same clinical study with PCOSⅠtype (non-obese).
Result:
1. PCOSⅠinduced infertility Clinical Study Results
(1) The pregnancy rate of treatment group 63%,the total efficiency was 90%. The pregnancy rate of control group46.7%,the total efficiency was 73.3%. Using statistical test, the data showed statistical significance(P＜0.05)
(2) Comparison of the two groups after treatment, the treatment group in amending the menstrual cycle, releasing lumbosacral pain and chest distress, as well as lower abdomen pain, vaginal discharge volume, sleepiness was superior to the control group. Statistically, there were significant differences (P＜0.05), Comparison of effects in TCM syndrome:the total efficiency in treatment group was 63.3%.33.3% of the control group. There were statistical differences (P＜0.05),
(3) Changes in level of endocrine:compared endocrinic hormones showed statistical differences in treatment group before and after treatment (P＜0.05), the level of T and LH decreased significantly, E2 increased. Although in the control group some reproductive hormones changed after treatment, there were not statistical significance P＞0.05
(4) The rat of treatment group was 85.5%, The rat of control group was 28.4% There were statistical significance between tow grouos.(P＜0.05)
2 PCOSⅡtype (obese) Clinical Study Results
(1) Clinical Observation on effect:The pregnancy rate of treatment group 46.7%,the total efficiency was 76.7%. The pregnancy rate of control group23.3%,the total efficiency was 46.7%. Using statistical test, the data showed statistical significance(P＜0.05)
(2) clinical performance and TCM syndrome:Compared between the two groups after treatment, the treatment group in amending the menstrual cycle, releasing lumbosacral pain and chest distress, as well as lower abdomen pain, vaginal discharge volume, sleepiness was superior to the control group. Statistically, there were significant differences (P＜0.05). Comparison of effects in TCM syndrome:the total efficiency of 63.3%* in the treatment group, it was 33.3% in the control group. There were statistical differences (P ＜0.05)
(3) Changes in level of endocrine:compared endocrinic hormones showed statistical differences in treatment group before and after treatment (P＜0.05). The levels of T and INS were declined markedly. Although in the control group some reproductive hormones changed after treatment, there were not statistical significance P＞0.05.
(4) The rat of treatment group was,39.5% The rat of control group was 19.0% There were statistical significance between tow grouos.(P＜0.05)
Conclusion:The intervention of PCOSⅠcan not only improve the general effect of PCOSⅠ, but also can effectively increase the pregnancy rate, reaching the purposes of a freely balanced menstruation and an unexpected pregnant.
PCOSⅠcan significantly decrease the following symptoms in PCOSⅠ:an abnormal menstrual cycle, the menstrual color of anomaly, the abnormal quantity of menstruation, abdomen pain, dizziness, lumbosacral pain, acne and dry mouth. Moreover, it has a noticeable improvements on the tongue. However, it has no improvements in furry because of a short duration.
PCOSⅠmethod can rapidly decrease the serum endocrine-T and LH of the patients who have PCOSⅠ(non-obese). On the other hand, it increases its E2. moreover, the ratio of LH/FSH is lower down before taking treatment, which implies that PCOSⅠmethod can improve the ovarian function, regulate the hypothalamic-pituitary-an ovarian axis' functions and correct the disorder endocrine environment.
PCOSⅠmethod:it can increase the ovulation rates and ovulation sends for PCOSⅠ(non-obese) type.
PCOSⅡcan increase both the total effect of PCOSⅡand effectively improve the pregnancy rate. However, in comparison with PCOSⅠ, PCOSⅡhas an obviously lower pregnancy rate
The intervention of PCOSⅡcan significantly improve the abnormal menstrual cycle, the menstrual color, the abnormal quantity, the abdomen pain, Chest Wan Man nausea, vaginal discharge volume, sleepiness, lumbosacral pain and other clinical manifestations. However, it only has a little improvement in the obesity, which may be related to the short duration.
By lowering insulin levels of the PCOSⅡ, PCOSⅡcan improve peripheral insulin's resistance, and regulating glucose and lipid metabolism in patients with PCOS to improve local abnormal ovarian endocrine status and lower the levels of androgen, thus making the ovulation function recovered, ovulation rate increased and reproductive function improved.
To PCOSⅠ, PCOSⅡhas a lower pregnancy rate, and while just adopting CC for treatment, PCOSⅡhas a even lower pregnancy rate. Moreover, it may be more complex than obesity exacerbating hyperinsulinemia, thus resulting in excessive androgen and producing a more complex PCOS endocrine.
In conclusion, the study is based on differential treatment of the patients identified on the basis of governance, with different types of herbs on PCOS conduct of governance. Chinese medicine can balanced the PCOS patients'inner irregular environment to promote the recovery of their reproductive function.
本研究是在辨病、辨证的基础上,把PCOSⅠ型(非肥胖型)辩证为肾虚血瘀；PCOSⅡ型(肥胖型)辨证为脾虚血瘀,应用导师2个经验方即PCOSⅠ号方和PCOS2号方分别对PCOS2型即PCOSⅠ型(非肥胖型)合PCOSⅡ型(肥胖型)进行治疗,探讨2方对PCOS2型的临床症状、内分泌激素、排卵率、妊娠率、总疗效的作用,以指导临床治疗PCOS所致不孕症最佳治疗方案,并为临床中成药的开发提供临床基础。
[研究方法]
根据文献研究和导师经验把PCOS所致不孕症按非肥胖和肥胖分为2型,在CC促排卵的基础上分别配合PCOS1号方治疗PCOSⅠ型；以PCOS2号方治疗PCOSⅡ型。
PCOSⅠ型(非肥胖型)临床研究：纳入病例标准符合PCOSⅠ型诊断标准及肾虚血瘀辨证标准,年龄在25岁至35岁已婚患者60例。按随机分配的原则分治疗组(中西结合组),对照组(西药组)各30例。
中西结合组(治疗组)：与月经或孕酮撤退性出血第1天测基础体温,第5天起应用克罗米芬胶囊(CC),每日一次,每次50mg口服,连用5天；同时加用PCOS1号方(即导师尤昭玲教授经验方)口服；对照组单用CC治疗。治疗组和对照组皆治疗3个月经周期为一疗程,用1个疗程,进行疗效统计。观察PCOS1号方对PCOSⅠ型的临床症状、内分泌激素、排卵率、妊娠率、总疗效的作用
PCOSⅡ型(肥胖型)临床研究：纳入病例标准符合PCOSⅡ型诊断标准及脾虚血瘀辨证标准,年龄在25岁至35岁已婚患者60例。按随机分配的原则分治疗组(中西结合组),对照组(西药组)各30例。治疗组与月经或孕酮撤退性出血第1天测基础体温,第5天起应用克罗米芬胶囊(CC),每日一次,每次50mg口服,连用5天；同时加用PCOS2号方(即导师尤昭玲教授经验方)口服,余下治疗和观察同PCOSⅠ型(非肥胖型)临床研究。
[结果]
1 PCOSⅠ型所致不孕证临床研究结果：
(1)治疗组妊娠率63.%,总有效率为90%；对照组妊娠率46.7%,总有效率为73.3%。两组比较,P<0.05,差异有显著性意义。
(2)两组治疗后比较,治疗组在改善月经周期、腰骶酸痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡方面优于对照组,经统计学处理,差异有显著性(P<0.05),治疗组中医证候总有效率为63.3%,对照组为33.3%,两组差异有显著性(P<0.05),
(3)血内分泌水平变化治疗组治疗前后比较内分泌激素有显著性变化(P<0.05),T、LH明显下降,E2升高。对照组治疗前后生殖内分泌激素虽稍有变化,但无统计学意义P>0.05
(4)两组周期排卵率比较,治疗组周期排卵率63.5%,对照组周期排卵率28.4%,两组周期排卵率比较有统计学意义(P<0.01)
2 PCOSⅡ型(肥胖型)临床研究结果
(1)临床疗效观察：治疗组妊娠率46.7%,总有效率为76.7%；对照组妊娠率23.3%,总有效率为46.7%。两组进行统计学检验,P<0.05差异有显著性意义。
(2)临床表现与中医证候治疗前后比较两组治疗后比较,治疗组在改善月经周期、腰骶酸痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡方面优于对照组,经统计学处理,差异有显著性(P<0.05)。治疗组中医证候总有效率为63.3%,对照组为33.3%,两组差异有显著性(P<0.05),
(3)血内分泌水平变化治疗组治疗前后比较内分泌激素有显著性变化(P<0.05),T、INS明显下降。对照组治疗前后生殖内分泌激素虽稍有变化,但无统计学意义P>0.05,
(4)两组周期排卵率比较治疗组周期排卵率39.5%,对照组周期排卵率19.0%,两组比较有统计学意义(P<0.01)。
[结论]
1. PCOSⅠ号方干预可提高PCOSⅠ型总疗效,并能有效提高妊娠率,达到调经助孕的目的。
2. PCOSⅠ号方可明显改善PCOSⅠ型中月经周期异常、月经色、量异常、经行小腹胀痛、头晕、腰骶酸痛、粉刺、口干症状。对舌脉也有明显改善作用。对多毛症状无改善,可能与疗程短有关。
3. PCOSⅠ号方能使非肥胖型PCOSⅠ型患者血清内分泌T、LH明显下降,E2升高,LH/FSH比值较治疗前降低,说明PCOSⅠ号方能改善卵巢功能,能调节下丘脑—垂体—卵巢轴的功能,纠正紊乱的内分泌环境。
4. PCOSⅠ号方对非肥胖型PCOSⅠ型可提高排卵率,有促排卵作用。
5. PCOSⅡ号方可提高肥胖型PCOSⅡ号总疗效,并能有效提高其妊娠率,但与PCOSⅠ型治疗妊娠率比较,PCOSⅡ型妊娠率明显低于PCOSⅠ型。
6. PCOSⅡ号方干预PCOSⅡ型可明显改善月经周期异常、月经色、量异常、经行小腹胀痛、胸脘满闷、经行小腹胀痛、带下量多、嗜睡、腰骶酸痛等临床表现。但对肥胖稍有改善,这可能与疗程短有关。
7. PCOSⅡ号方通过降低PCOSⅡ型胰岛素水平,改善外周胰岛素抵抗状态,调节糖、脂代谢以改善PCOS患者的卵巢局部异常的内分泌状态,降低雄激素水平,使排卵功能恢复,排卵率增加,改善生殖机能。
8. PCOSⅡ型比较PCOSⅠ型妊娠率较低,单用CC治疗PCOSⅡ型妊娠率更低,可能与肥胖可加剧高胰岛素血症,导致过多的雄激素产生,使PCOS内分泌更为复杂
综上所述,本研究在辨证施治的基础上辨病论治,以不同的方药对PCOS分型进行论治。中药可调节PCOS患者失调的内环境,促使其生殖功能的恢复。
Object:Polycystic ovary syndrome is a kind of endocrine disease that with different causes and polymorphism clinical manifestation. Moreover, PCOS is also a main reason that causes infertility because of not having ovary sends.
The thesis intends to divide the PCOSⅠinto kidney efficiency and blood stasis and PCOSⅡinto spleen efficiency and blood stasis, on the basis of the researches of diseases and actual examples. Moreover, the author also intends to adopt her tutor's two excellent experiences-PCOSⅠmethod and PCOSⅡmethod to have a thorough study on PCOS 2, thus exploring the influence of the two methods on PCOS 2, including its clinical manifestations, inner incretion hormone, the ovary sends'rate, the pregnancy rate and the general effect, and instructing a clinical basis on the development of Chinese medicine.
Methods:The author has not only divided the infertility caused by PCOS into obese and non-obese, on the basis of the established researches and the author's actual experience, but also has adopted the corresponding way of PCOS 1 to cure PCOSⅠand PCOS 2 for PCOSⅠon the basis of the research of CC, which helps to speed up the ovary sends.
Clinical research of PCOSⅠ(Non-obese):A Case standards into line with PCOSⅠdiagnostic standard and kidney deficiency and blood stasis dialectical standard, the age of 25-year-old to 35-year-old married in 60 cases. According to the random distribution principle, it is divided into the treatment group (combination of Chinese and Western group) and the contrastive group (WM group) of the 30 cases.
Treatment group and menstruation or progesterone withdrawal bleeding:have a temperature measurement basis at the first day, take the medicine clomiphene capsules (CC) after five days, once daily,50 mg orally each day for five days at the same time, plus the PCOS2 (i.e. the author's tutor Professor You Zhaoling's experience), oral. Treatment group and the control group were three of the menstrual cycle for treatment with a course of treatment and an efficient statistics. The observation side PCOS1 method plays a role in the clinical symptoms, endocrine hormone, ovulation rate, pregnancy rate and the total effect of PCOSⅠ
PCOSⅡtype (obese) Clinical Research:A Case standards into line with PCOSⅡdiagnostic criteria and spleen deficiency and blood stasis standards, the age of 25-year-old to 35-year-old married in 60 cases. According to the random distribution principle, it is divided into the treatment group (combination of Chinese and Western), the control group (WM group) of the 30 cases. Treatment group and menstruation or progesterone withdrawal bleeding:have a temperature measurement basis at the first day, take the medicine clomiphene capsules (CC) after five days, once daily,50 mg orally each day for five days at the same time, plus the PCOS2 (i.e. the author's tutor Professor You Zhaoling's experience), oral, and the remaining treatment and observation has the same clinical study with PCOSⅠtype (non-obese).
Result:
1. PCOSⅠinduced infertility Clinical Study Results
(1) The pregnancy rate of treatment group 63%,the total efficiency was 90%. The pregnancy rate of control group46.7%,the total efficiency was 73.3%. Using statistical test, the data showed statistical significance(P＜0.05)
(2) Comparison of the two groups after treatment, the treatment group in amending the menstrual cycle, releasing lumbosacral pain and chest distress, as well as lower abdomen pain, vaginal discharge volume, sleepiness was superior to the control group. Statistically, there were significant differences (P＜0.05), Comparison of effects in TCM syndrome:the total efficiency in treatment group was 63.3%.33.3% of the control group. There were statistical differences (P＜0.05),
(3) Changes in level of endocrine:compared endocrinic hormones showed statistical differences in treatment group before and after treatment (P＜0.05), the level of T and LH decreased significantly, E2 increased. Although in the control group some reproductive hormones changed after treatment, there were not statistical significance P＞0.05
(4) The rat of treatment group was 85.5%, The rat of control group was 28.4% There were statistical significance between tow grouos.(P＜0.05)
2 PCOSⅡtype (obese) Clinical Study Results
(1) Clinical Observation on effect:The pregnancy rate of treatment group 46.7%,the total efficiency was 76.7%. The pregnancy rate of control group23.3%,the total efficiency was 46.7%. Using statistical test, the data showed statistical significance(P＜0.05)
(2) clinical performance and TCM syndrome:Compared between the two groups after treatment, the treatment group in amending the menstrual cycle, releasing lumbosacral pain and chest distress, as well as lower abdomen pain, vaginal discharge volume, sleepiness was superior to the control group. Statistically, there were significant differences (P＜0.05). Comparison of effects in TCM syndrome:the total efficiency of 63.3%* in the treatment group, it was 33.3% in the control group. There were statistical differences (P ＜0.05)
(3) Changes in level of endocrine:compared endocrinic hormones showed statistical differences in treatment group before and after treatment (P＜0.05). The levels of T and INS were declined markedly. Although in the control group some reproductive hormones changed after treatment, there were not statistical significance P＞0.05.
(4) The rat of treatment group was,39.5% The rat of control group was 19.0% There were statistical significance between tow grouos.(P＜0.05)
Conclusion:The intervention of PCOSⅠcan not only improve the general effect of PCOSⅠ, but also can effectively increase the pregnancy rate, reaching the purposes of a freely balanced menstruation and an unexpected pregnant.
PCOSⅠcan significantly decrease the following symptoms in PCOSⅠ:an abnormal menstrual cycle, the menstrual color of anomaly, the abnormal quantity of menstruation, abdomen pain, dizziness, lumbosacral pain, acne and dry mouth. Moreover, it has a noticeable improvements on the tongue. However, it has no improvements in furry because of a short duration.
PCOSⅠmethod can rapidly decrease the serum endocrine-T and LH of the patients who have PCOSⅠ(non-obese). On the other hand, it increases its E2. moreover, the ratio of LH/FSH is lower down before taking treatment, which implies that PCOSⅠmethod can improve the ovarian function, regulate the hypothalamic-pituitary-an ovarian axis' functions and correct the disorder endocrine environment.
PCOSⅠmethod:it can increase the ovulation rates and ovulation sends for PCOSⅠ(non-obese) type.
PCOSⅡcan increase both the total effect of PCOSⅡand effectively improve the pregnancy rate. However, in comparison with PCOSⅠ, PCOSⅡhas an obviously lower pregnancy rate
The intervention of PCOSⅡcan significantly improve the abnormal menstrual cycle, the menstrual color, the abnormal quantity, the abdomen pain, Chest Wan Man nausea, vaginal discharge volume, sleepiness, lumbosacral pain and other clinical manifestations. However, it only has a little improvement in the obesity, which may be related to the short duration.
By lowering insulin levels of the PCOSⅡ, PCOSⅡcan improve peripheral insulin's resistance, and regulating glucose and lipid metabolism in patients with PCOS to improve local abnormal ovarian endocrine status and lower the levels of androgen, thus making the ovulation function recovered, ovulation rate increased and reproductive function improved.
To PCOSⅠ, PCOSⅡhas a lower pregnancy rate, and while just adopting CC for treatment, PCOSⅡhas a even lower pregnancy rate. Moreover, it may be more complex than obesity exacerbating hyperinsulinemia, thus resulting in excessive androgen and producing a more complex PCOS endocrine.
In conclusion, the study is based on differential treatment of the patients identified on the basis of governance, with different types of herbs on PCOS conduct of governance. Chinese medicine can balanced the PCOS patients'inner irregular environment to promote the recovery of their reproductive function.
引文
[1]程泾.实用中西医结合不孕不育诊疗学[M].第一版.北京：中国中医药出版社,2001,334.
[2]李美芝.妇科内分泌学[M].北京：人民军医出版社,2000.35-40,199-214.
[3]葛秦生,孙亦彬,刘士廉,等.临床生殖内分泌学[M].北京：科学技术文献出版社,2001.186-192,386-401.
[4]Mantzoros CS,Dunaif A,Flier JS.Leptin concentrations inthe polyeysfie VAD syndrome[J].J Clin Endocrinol Metab.
[5]Balen AH.Hypersecretion of luteinizing homome and poly-cystic ovary syndrome[J].Hum Reprod,1993,8:123.
[6]曹泽毅.中华妇产科学[M].北京：人民卫生出版社,2007.
[7]Fedorcsak P, S toreng R, D ale P O, et al. L ep tin and lep tinbinding activity in the p reovμlatory follicle of polycystic ovarysyndrome patients [J].Scand J C lin L ab Invest,2000,60:649-655.
[8]冯淑英.PCOS胰岛素抵抗发生机制与无排卵[J].实用妇产科杂志[J],2005,21(9)：518.
[9]范琅娣.卵巢病理与临床[M].北京：人民卫生出版社,1998.377-378
[10]Lo fier S.Aust G.Kohler U.et al.Evidence of leptin expression in normal and polycystic human ovaries.Mol Hum Reprod,2001,7(12):1143-1149
[11]Fedorcsak P,Storeng R,Dale PO,et al.Leptin and leptin binding activity in the Preovμlatory follicle of polycystic ovary syndrome patents.Scand J Clin Lab Invest,2000,60(8):649-655.
[12]Maliqueo M,Piwooka V,Perez Bravo F.et al.Evalustion of acute efect of GnRHadministration on leptin secretion in normal andhype-randrogenic women.Rev Med Chil.2000.128(5):460-466.
[13]Lee. MT,Anderson. E and Lee GY. Changes in ovarian morpho[ogy and serum hormones in the rat after treatment with hydroepiandrosterone[J]. Anat.Rec I991; 231:185-192
[14]Anderson.E, Lec GY,O brien. K. Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model:hperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles [J].Anat.Rec,1997,249:44-53.
[15]李小永.多囊卵巢综合征[J].国外医学妇产科学分册,2003.30(1)：34
[16]Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsμlinism in polycystic ovarian diseasc [J]Clin Endocrinol Metab,1980,50:113.
[17]冯淑英.PCOS胰岛素抵抗发生机制与无排卵[J].实用妇产科杂志,2005,21(9)：517.
[18]Dunaif A.Insμlin resistance and the polycystic ovary syndrome:mechan ism and implications for pathogenesis Endocr Rev,1997,18:774.
[19]INmaif A,Thomas A Current concepts in the polycystic ovary syn drome.Annu Rev Med,2001,52:401.
[20]ShμldinerAR, Yang R,GongDW.Resistin,obesity,andinsμlin resistance-the emerging role of the adipocyte as an endocrine organ[J].NEngl Med,2001,345(18):1345-1346.
[21]Mendonca HC,Montenegro RM.FoSS MC.et al.Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome.Braz J Med Biol Res,2004.37(5):729-736.
[22]张跃辉,侯丽辉.瘦素与多囊卵巢综合征关系的研究进展[J].国外医学妇产科学分册,2005,32(5)：298.
[23]Kolaczynski JW,Nyce MR,Considine RV,et al.Acute and chronic efect of insμlin on Leptin production in human studies in vivo and in vitro.Diabetes,1996,45(5):699.
[24]Pirwary IR, Fleming R, Greer IA, etal. Lipids and lipop rotein subfractions in women with PCOS:relationship to metabolic and endocrine parameters [J]. Clin Endocrinol,2001,54:447-453.
[25]Steppan C M,Bailey S T,Bhat S,el al Fhe hormone resistin links obesity to diabetes[J].Nature,2001.409(6818):307-312.
[26]Dimitrios P,Georgios K,Anargyros K,el al.Serum resistin levelsin women with polycystic ovary syndrome[J].Fertil teril,2004,81(2):361-366.
[27]Sayin NC.Gueer F.Balkanli-Kaplan P.et al.Elevated serum TNF-otlevels in norm al-weight WOl'iflen with polyeystic ovaries or the polyeys-tic ovary syndrome.J Reprod Med,2003,48(3):165-170.
[28]Peral B.Millan JLS.Castello R.et al.Th methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene(TNFRSF1B)is associated with the polycystie ovary syndrome and hyperandrogenism.J Clin Endocrinol Metab.2oo2.87(8):3977-3983.
[29]Gonzalez F.Thusu K.Abdel-Rahman E.et al.Elevated serum levels of tumor necrosis factor alpha in norm al-weight women with polyeys-tic ovary syndrome.Metabolism.1999.48f4):437-441.
[30]Panidis D.Kcurtis A.Farmakiotis D.et al.Serum adiponeetin levels in women with polycystie ovary syndrome.Hum Reprod,2003,18(9):1790-1796.
[31]Roberts VJ,Barth S,el-Roeiy A,et al.Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome.[J]Clin Endocrinol Metab,1994,79:1434-1439.
[32]Toshihiro F,Yisrael S. Dynamics of inhibin subunit and follistatin mRNA during development of normal and ploycystic ovary syndrome follicles. [J]. Clin Endocrinol Metab,2001,86(9):4206-4151.
[33]Norman RJ,Milner CR,Groome NP,et al. Circμlating follistatin oncentrations are higher and active concertrations are lower in polycystic ovarian syndrome. Hum Reprod,2001,16 (4):668-6721.
[34]徐雯,王元佩,赵采,等.多囊卵巢综合征患者血清、卵泡液中胰岛素样生长因子—Ⅰ水平研究[J].福建医药杂志,2004,26(4)：113.
[35]初永丽,邱红玉,孙永玉.多囊卵巢综合征患者血清肿瘤坏死因子-a的检测及意义[J].实用妇产科杂志,2003,3：167-168.
[36]Diamanti Kandarak is E, BartzisM I, Bergiele A T, et.Microsatellite polymo rph ism (tttta) (n) at-528 base pairs of gene CYP1 la lphauences hyperandro genem ia in patients with polycystic ovary syndrome[J]. ertil S teril,2000,73 (4):735-741.
[37]Gao YQ, Qiao J, Zhang XW, et al. The androgen recep tor CAG repeat polymorphism and polycystic orarvy syndrome [J]. NatlMed J China,2003,83:598-599.
[38]Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleo tide po lymo rph ism at the tyro sine k inase domain of the insμlin receptor gene is associated w ith polycystic ovary syndrome[J]. Fertil S teril,2002,78 (6):1240-1243.
[39]Lindell K, Bennett PA, Itoh Y, et al. L ep tin receptor5'untranslated regions in the rat:relative abundance, genom ic o rganization and relation to putative response elements[J]. M ol Cell E nd ocrinol,2001,172 (1-2):37-45.
[40]谭丽,郑英,朱桂金等.LH-p基因突变与多囊卵巢综合征关系的研究[J].中国实用妇科与产科杂志,2005,21(6)：358-359.
[41]Tong Y, L iaoWX, Roy AC, et al. A ssociation of A cc I polymorphism in the follicle stimμlating hormone bet gene with polycystic ovary syndrome [J]. Fertil S teril,2000,74 (6):1233-1236.
[42]Peral B, San M illan JL, Castello R, et al. Comment:the meth ionine 196 arginine polymorphism in exon 6 of the TN F recep to r2 gene (TN FRSF1B) is associated w ith the polycystic ovary syndrome and hyperandrogenism [J]. J C lin E nd ocrinolM etab, 2002,87 (8):3977-3983.
[43]肖承宗.对多囊卵巢综合征所致不孕的认识与治疗.江苏中医药[J].2006.27(3)：8.
[44]马素侠,梅本华,等.六味地黄丸加味治疗多囊卵巢综合征疗效分析[J].新疆中医药,2000,18(3)：22-23.
[45]罗元恺,郑国平.以补肾为主治疗更年期综合征临床研究[J].中国医药学报,1995,(2)：25.
[46]史莲花,韩宁.楮玉霞教授治疗多囊卵巢综合征的经验[J].四川中医,2004,22(1)：1.
[47]朱红鹏,张龚,等.难治性多囊卵巢综合征的中西结合治疗[J].中国民间疗法,2001,9(8)：9-10.
[48]黎小斌,李丽芸.导痰种子方联合克罗米芬治疗多囊卵巢综合征[J].实用医学杂志,2000,16(4)：330-331.
[49]卢清艺.加味补中益气汤和克罗米芬治疗多囊卵巢综合征[J].河北医科大学学报,2000,21(2)：113.
[50]侯璟玟,俞瑾等.中药天癸方治疗多囊卵巢综合征中高雄激素高胰岛素血症的研究[J].中国中西医结合杂志,2000,20(8)：589-592
[51]陈玲,王丽英.健脾益肾化痰汤治疗多囊卵巢综合征30例[J].江苏中医,1999,20(7)：31.
[52]王佳楣.中西药物对多囊卵巢综合征生殖和代谢功能的影响[J].山东中医药大学学报,2002,26(3)：203.
[53]万朝霞.谈勇教授治疗多囊卵巢综合征的临证经验[J].黑龙江中医药,2003,5：31.
[54]刘瑞芬.以补、调、通三步疗法为主治疗多嶷卵巢综合征[J].江苏中医药,2006,27(3)：10.
[55]夏桂成,用动静观指导滋阴补肾调治多囊卵巢综合征[J].江苏中医药,2006,27(3)：12.
[56]杨悦娅.朱南孙治疗多秦卵巢综合征的思路与方法[J].上海中医药杂志,2006,40(1)：43-44.
[57]Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin through pregnancy in women with polycystic syndrome appears to safely reduce first-trimester spontaneous abortion:a pilot study. Fertil Steril,2001,75:47-51.
[58]Glueck CJ, Wang P, Smith S, et al. Metformin-induced resumption oI normal menses in 39 of 43 (91%)previously amenorrheic women with polycystic ovary syndrome. Metabolism,1999,48:511-519.
[59]Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhihitor aclivily:an independent risk factor for the high miscarrige rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999,48:1589-1595.
[60]Mikola M, Hiilesmaa V, Halttumen M, et al. Obsteric outcome in women with polycystic ovarian syndrome. Hum Repord,2001,16:226-229.
[61]Solomon CG, Carroll JS, Okamura K, et al. Higher cholesterol and insμlin levels in pregnancy are associated with increased risk for for prenancy-induced hypertension. Am J Hypertens,1999,12(3):276-282.
[62]Dale BS, Tanho T, Storeng R, et al. Insμlin resistance and the polycystic ovarian syndrome:recent advances. Gyvnecol Obstel Invest,2002,54(2):94-98.
[63]Talbott E0, Zborowekii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascμlar disease? Review of the evidence.Minerva Ginecol,2004,56 (1):27-39.
[64]]Birdsall MA. Farquhar CM. Polycystic ovaries in pre-and post-menopausal women.Clin Endocrinol,1996,44:89-93.
[65]Robinson S et al. Dyslipidem is is associated with insμlin resistance in women with polycystic ovaries.Clin En-docxinol,1996,44:277.
[66]Guzick DS Talboll E0, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome:initial resμlls from case-control study. Am J Obstet Gynecol,1996,174:1224-1229.
[67]OLeary DH, Polka JF Wolfson SK, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardio Vascμlar Health Study.CHS Collaborative Research Group. Stroke,1991,22:1155-1163.
[68]Festa A, D'Agostino J r R, Howard G, et al. Chronic subclinical in-flammation as part of the insμlin resistance syndrome:the Insμlin Resistance Atherosclerosis Study (IRAS) [J]. Circμlation,102:42-47.
[69]Laure MP, Katriina R, Aimo R, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome[J].Clinical Endocrinology & Metabolism,2003,88 (10):4649-4654.
[70]Wild S, Pierpoint T, McKeigue P, et al. Cardiovascμlar disease in women with polycystic ovary syndrome at long-term follow-up:a retrospective cohort study.Clin Endocrinol,2000,52:595-600.
[71]Norman R J,Masters L,Milner C R,et al.Relative of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndronme[J].Hum Reprod,2001,16:1995-1998.
[72]高劲松,沈铿,郎景和,等.子宫内膜癌患者的临床分析.中华妇产科杂志[J].2004,39(3)：159-161.
[73]Schwimmer J B,Khorram O,Chiu V et al.Abnormal aminotransferase activity in women with polycystic ovarian syndronme[J].Fertil Steril,2005,83(2):498-497.
[74]张丽珠主编.临床生殖内分泌与不孕症.第一版.北京：科学出版社,2001.374-468.
[75]李岩,陶华.妈富隆治疗40例多囊卵巢综合征疗效分析[J].中国计划生育学杂志,2001,70(2)：103.
[76]林琳,刘复权.复方醋酸环丙孕酮治疗多囊卵巢综合征[J].国外医学妇幼保健分册,2003,14(6)：371-372.
[77]刘泽安,薛元明,蔡琼等.二甲双胍对多囊卵巢综合征伴假性黑棘皮病和胰岛素抵抗的作用[J].中国医生杂志,2003,5(3)：353-354.
[78]宋菊香,沈鸿敏,李建业,等.二甲双胍对多囊卵巢综合征患者纤溶系统、内分泌、代谢的影响及对耐氯米芬的作用[J].中华妇产科杂志,2002,37(2)：89.
[79]郑志群,李美芝,林益川,等.罗格列酮对多囊卵巢综合征胰岛素抵抗及高雄激素血症的治疗研究[J].中华妇产科杂志,2002,37(5)271-273.
[80]许志保.中药人工周期疗法的应用[J].江苏中医,1997,18(11)：12.
[81]郝兰枝,魏俊英.中药人工周期治疗青春期多囊卵巢综合征40例[J].中药研究,2003,16(3)：36.
[82]侯璟玟,俞瑾,魏美娟.中药天癸方治疗多囊卵巢综合征高雄激素高胰岛素的研究[J].中国中西医结合杂志,2000,20(8)：589-592.
[83]吕琪,初琦,阴春霞,等.二甲双胍和达因-35联合应用治疗多囊卵巢综合征40例分析[J].中国妇幼保健,2004,19(2)：93.
[84]冯玉昆,陆义芹,孙跃平,等.达英-35联合二甲双胍治疗肥胖型PCOS的临床探讨[J].昆明医学院学报,2005,26(1)：47-50.
[85]张富青,邹芳,崔玉琳,等.二甲双胍联合妈富隆治疗多囊卵巢综合征临床分析[J].中原医刊,2004,31(8)：61.
[86]王婕,张凌,赵丽萍,等.二甲双胍辅助克罗米芬用于多囊卵巢综合征促卵泡发育的疗效观察[J].生殖与避孕,2005,25(2)125-126.
[87]任建民,吕怡静,唐宽晓,等.罗格列酮联合二甲双胍治疗多囊卵巢综合征的临床疗效观察[J].现代妇产科进展,2004,13(3)：197-199.
[88]王洪萍,刘默,王静,等.吡格列酮联合二甲双胍治疗PCOS伴IR疗效观察[J].山东医药,2005,45(25)：56.
[89]郑志群,林益川,马炎辉等.GnRH-a加达因-35治疗多囊卵巢综合征[J].实用妇产科杂志,2001,17(3)：165-166.
[90]袁超燕,陈宏芳.腹腔镜手术配伍药物治疗多囊卵巢综合征性不孕[J].湖北民族学院学报·医学版,2002,19(2)：56.
[91]邵瑞云,郎丰君,蔡金凤,等.补肾活血中药加克罗米芬治疗多囊卵巢综合征所致不孕的临床观察[J].中国中西医结合杂志,2004,24(1)：41-43.
[92]黎小斌,李丽芸.导痰种子方联合克罗米芬治疗多囊卵巢综合征[J].实用医学杂志,2000,16(4)：330-331.
[93]侯丽辉,马丽君,于凤娟,等.性激素监测中西药治疗多囊卵巢综合征16列[J].中医药学报,2000,28(1)：48-49.
[94]陈翔.中西医结合治疗多囊卵巢综合征之不孕38例[J].黑龙江中医药,20003,1：14.
[95]张明敏,黄光英,陆付耳,等.中药联合氯米芬治疗耐氯米芬多囊卵巢综合征的临床研究[J].中华实用中西医杂志,2003,3(16)：157-159.
[96]黎小斌,李丽芸,黄建玲,等.腹腔镜手术辅以补肾化痰中药治疗多囊卵巢综合征[J].新药与临床药理,2002,13(2)：23.
[97]Glued CJ, Papanna R,Wang P1Incidence and treatment of metabolic syndrome in newly refrred women with firmed olycystic ovarian syndrome1Metabolism,2003,52 (7):908-915
[98]Sesti G,Federid M,Lauro D,et all Molecμlar mechanism of insulin resistance in type diabetes mellitus:role of the insμlin receptor variant forms,Diabetes Metab Res ev,2001,17 (5):363-373
[99]高献青,孙宝治.肥胖型与非肥胖型PCOS患者内分泌代谢状态及治疗观察[J].山东医药.2004,44(24)：20-21
[100]丁彩飞,刘丽华,李美芝.肥胖与非肥胖多囊卵巢综合征患者的临床特征[J].中国煤炭工业医学杂志.2002,5(6)：553-554
[101]林金芳,李昕,朱铭伟.多囊卵巢综合征的分型探讨[J].中华妇产科杂志.2006,41(10)：685-685.
[102]乐杰.妇产科学.北京：人民卫生出版社,2005,第6版：344-345.
[103]郑筱萸.中药新药临床研究指导原则.中药新药治疗月经不调的临床研究指导原则[M].北京：中国医药科技出版社,2002：239-241.
[104]张玉珍.中医妇科学.北京：中国中医药出版社,2002,第一版：123-124.
[105]向坤,李云,张丽娟.排卵功能障碍性不孕的机制[J].山东中医杂志,2000,6,19(5)：326-327.
[106]Goren S,Oron Y,Debel N,et al.Rat oocye maturation:role of calcium in hormone action.Mol Cell Endocrinol,1990,72(2):131-138.
[107]秦达念,佘百蓉,佘运初,等.菟丝子黄酮对实验动物及人绒毛组织生殖功能的影响[J].中药新药与临床药理,2000,11(6)：349-351,386-387.
[108]归绥琪,俞瑾,魏美娟等.补肾中药对雄激素致不孕大鼠垂体、卵巢及肾上腺作用的实验研究[J].中国中西医结合杂,1997,17(12)：735-728.
[109]杨宗孟.女宝治疗女子肾虚不孕46例临床观察初步小结[J].长春中医学院学报,1988,4(10)：10.
[110]李炳如,余运初.补肾对下丘脑-垂体-性腺轴功能的影响[J].中医杂志,1984,25(7)：63-64.
[111]张华,冉雪梦,陈芊等.补肾活血方增强子宫内膜降钙素基因表达的临床研究[J].中国计划生育学杂.2007,137(3)：173.
[112]Nestler JE.Insμlin and adrenal androgens. Reproductive Endocrinology,1994,12 (1):1-5.
[113]华等,张巨明,柴松岩,等.肾健脾养血通利法治疗多囊卵巢综合征临床资料分析[J].北京中医杂志,2002,21(6)：323-326.
[114]Gambineri A, Pelusi C, Vicennati V. et al. Obesity an d the polycystic ovary syndrome. Int J Obes Relat Metab Disord,2002,26:883-896.
[115]Glued CJ, Papanna R,Wang P1Incidence and treatment of metabolic syndrome in newly refrred women with confirmed polycystic ovarian syndrome 1 Metabolism,2003,52 (7):908-9151.
[116]Sesti G,Federid M,Lauro D,et all Molecμlar mechanism of insulin resistance in type diabetes mellitus:role of the insμlin receptor variant forms,Diabetes Metab Res Rev,2001,17(5):363-3731.
[117]Poretsky L.Clemons K, Bogovich K Hyperinsμlinemia and homan Chorionic gonadotropin synergistically promote the growth of ovarian follicμlar cysts in rats. Metabolism.1992.41:903-910.
[118]Filicor M, Flamignic c,cognigni G,et al. Increased insμlin secretion in patients with mμltifollicμlar and polycystic ovaries and its impact onovμlation induction.Fertil steril 1994.62:279-285.
[1]程泾.妇科疑难病现代中医诊断与治疗。北京：人民卫生出版社,2003：250。
[2]张丽珠主编。临床生殖内分泌与不孕症。第一版。北京：科学出 版社,2001.374-468。
[3]李岩,陶华。妈富隆治疗40例多囊卵巢综合征疗效分析。中国计划生育学杂志。2001,70(2)：103.
[4]林琳,刘复权。复方醋酸环丙孕酮治疗多囊卵巢综合征。国外医学妇幼保健分册。2003,14(6)：371-372。
[5]刘泽安,薛元明,蔡琼。二甲双胍对多囊卵巢综合征伴假性黑棘皮病和胰岛素抵抗的作用。中国医生杂志。2003,5(3)：353-354。
[6]宋菊香,沈鸿敏,李建业,等。二甲双胍对多囊卵巢综合征患者纤溶系统、内分泌、代谢的影响及对耐氯米芬的作用。中华妇产科杂志。2002,37(2)：89。
[7]郑志群,李美芝,林益川,等。罗格列酮对多囊卵巢综合征胰岛素抵抗及高雄激素血症的治疗研究。中华妇产科杂志。2002,37(5)271-273
[8]张爱荣,徐永萍,傅艺冰,等。腹腔镜电凝打孔治疗多囊卵巢综合征20例临床观察。腹腔镜外科杂志。2001,6(1)：36-37。
[9]王庆一,杨桂艳。腹腔镜多点活检对多囊卵巢综合征的治疗作用。实用医学杂志。2001,17(3)：219-220。
[10]张萍,凌奋,汤蕴琦。腹腔镜单极电针烧灼治疗多囊卵巢综合征。中国现代手术学杂志。2001,5(4)：270-271.
[11]许志保。中药人工周期疗法的应用。江苏中医,1997,18(11)：12。
[12郝兰枝,魏俊英。中药人工周期治疗青春期多囊卵巢综合征40 例。中药研究。2003,16(3)：36。
[13]侯璟玟,俞瑾,魏美娟。中药天癸方治疗多囊卵巢综合征高雄激素高胰岛素的研究。中国中西医结合杂志。2000,20(8)：589-592。
[14]吕琪,初琦,阴春霞等。二甲双胍和达因-35联合应用治疗多囊卵巢综合征40例分析。中国妇幼保健。2004,19(2)：93。
[15]冯玉昆,陆义芹,孙跃平等。达因-35联合二甲双胍治疗肥胖型PCOS的临床探讨。昆明医学院学报,2005,26(1)：47-50。
[16]张富青,邹芳,崔玉琳等。二甲双胍联合妈富隆治疗多囊卵巢综合征临床分析。中原医刊,2004,31(8)：61。
[17]徐爱萍,施蔚虹。克罗米芬联合二甲双胍治疗多囊卵巢综合征疗效观察。齐齐哈尔医学院学报。2003,24(10)：1112。
[18]赵海波,芦小娟,任菊霞等。二甲双胍与克罗米芬联合治疗难治性多囊卵巢综合征。第四军医大学学报。20003,24(6)：560-562。
[19]王婕,张凌,赵丽萍等。二甲双胍辅助克罗米芬用于多囊卵巢综合征促卵泡发育的疗效观察。生殖与避孕。2005,25(2)125-126。
[20]任建民,吕怡静,唐宽晓等。罗格列酮联合二甲双胍治疗多囊卵巢综合征的临床疗效观察。现代妇产科进展,2004,13(3)：197-199。
[21]王洪萍,刘默,王静。吡格列酮联合二甲双胍治疗PCOS伴IR疗效观察。山东医药,2005,45(25)：56
[22]郑志群,林益川,马炎辉等。GnRH-a加达因-35治疗多囊卵巢综 合征。实用妇产科杂志。2001,17(3)：165-166。
[23]袁超燕,陈宏芳。腹腔镜手术配伍药物治疗多囊卵巢综合征性不孕。湖北民族学院学报·医学版。2002,19(2)：56。
[24]邵瑞云,郎丰君,蔡金凤等。补肾活血中药加克罗米芬治疗多囊卵巢综合征所致不孕的临床观察。中国中西医结合杂志,2004,24(1)：41-43。
[25]黎小斌,李丽芸。导痰种子方联合克罗米芬治疗多囊卵巢综合征。实用医学杂志,2000,16(4)：330-331。
[26]侯丽辉,马丽君,于凤娟,等。性激素监测中西药治疗多囊卵巢综合征16列。中医药学报,2000,28(1)：48-49。
[27]陈翔。中西医结合治疗多囊卵巢综合征之不孕38例。黑龙江中
医药。20003,1：14。
[28]张明敏,黄光英,陆付耳,等。中药联合氯米芬治疗耐氯米芬多囊卵巢综合征的临床研究。中华实用中西医杂志。2003,3(16)：157-159。
[29]黎小斌,李丽芸,黄建玲,等。腹腔镜手术辅以补肾化痰中药治疗多囊卵巢综合征。新药与临床药理,2002,13(2)：23。
[2]李美芝.妇科内分泌学[M].北京：人民军医出版社,2000.35-40,199-214.
[3]葛秦生,孙亦彬,刘士廉,等.临床生殖内分泌学[M].北京：科学技术文献出版社,2001.186-192,386-401.
[4]Mantzoros CS,Dunaif A,Flier JS.Leptin concentrations inthe polyeysfie VAD syndrome[J].J Clin Endocrinol Metab.
[5]Balen AH.Hypersecretion of luteinizing homome and poly-cystic ovary syndrome[J].Hum Reprod,1993,8:123.
[6]曹泽毅.中华妇产科学[M].北京：人民卫生出版社,2007.
[7]Fedorcsak P, S toreng R, D ale P O, et al. L ep tin and lep tinbinding activity in the p reovμlatory follicle of polycystic ovarysyndrome patients [J].Scand J C lin L ab Invest,2000,60:649-655.
[8]冯淑英.PCOS胰岛素抵抗发生机制与无排卵[J].实用妇产科杂志[J],2005,21(9)：518.
[9]范琅娣.卵巢病理与临床[M].北京：人民卫生出版社,1998.377-378
[10]Lo fier S.Aust G.Kohler U.et al.Evidence of leptin expression in normal and polycystic human ovaries.Mol Hum Reprod,2001,7(12):1143-1149
[11]Fedorcsak P,Storeng R,Dale PO,et al.Leptin and leptin binding activity in the Preovμlatory follicle of polycystic ovary syndrome patents.Scand J Clin Lab Invest,2000,60(8):649-655.
[12]Maliqueo M,Piwooka V,Perez Bravo F.et al.Evalustion of acute efect of GnRHadministration on leptin secretion in normal andhype-randrogenic women.Rev Med Chil.2000.128(5):460-466.
[13]Lee. MT,Anderson. E and Lee GY. Changes in ovarian morpho[ogy and serum hormones in the rat after treatment with hydroepiandrosterone[J]. Anat.Rec I991; 231:185-192
[14]Anderson.E, Lec GY,O brien. K. Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model:hperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles [J].Anat.Rec,1997,249:44-53.
[15]李小永.多囊卵巢综合征[J].国外医学妇产科学分册,2003.30(1)：34
[16]Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsμlinism in polycystic ovarian diseasc [J]Clin Endocrinol Metab,1980,50:113.
[17]冯淑英.PCOS胰岛素抵抗发生机制与无排卵[J].实用妇产科杂志,2005,21(9)：517.
[18]Dunaif A.Insμlin resistance and the polycystic ovary syndrome:mechan ism and implications for pathogenesis Endocr Rev,1997,18:774.
[19]INmaif A,Thomas A Current concepts in the polycystic ovary syn drome.Annu Rev Med,2001,52:401.
[20]ShμldinerAR, Yang R,GongDW.Resistin,obesity,andinsμlin resistance-the emerging role of the adipocyte as an endocrine organ[J].NEngl Med,2001,345(18):1345-1346.
[21]Mendonca HC,Montenegro RM.FoSS MC.et al.Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome.Braz J Med Biol Res,2004.37(5):729-736.
[22]张跃辉,侯丽辉.瘦素与多囊卵巢综合征关系的研究进展[J].国外医学妇产科学分册,2005,32(5)：298.
[23]Kolaczynski JW,Nyce MR,Considine RV,et al.Acute and chronic efect of insμlin on Leptin production in human studies in vivo and in vitro.Diabetes,1996,45(5):699.
[24]Pirwary IR, Fleming R, Greer IA, etal. Lipids and lipop rotein subfractions in women with PCOS:relationship to metabolic and endocrine parameters [J]. Clin Endocrinol,2001,54:447-453.
[25]Steppan C M,Bailey S T,Bhat S,el al Fhe hormone resistin links obesity to diabetes[J].Nature,2001.409(6818):307-312.
[26]Dimitrios P,Georgios K,Anargyros K,el al.Serum resistin levelsin women with polycystic ovary syndrome[J].Fertil teril,2004,81(2):361-366.
[27]Sayin NC.Gueer F.Balkanli-Kaplan P.et al.Elevated serum TNF-otlevels in norm al-weight WOl'iflen with polyeystic ovaries or the polyeys-tic ovary syndrome.J Reprod Med,2003,48(3):165-170.
[28]Peral B.Millan JLS.Castello R.et al.Th methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene(TNFRSF1B)is associated with the polycystie ovary syndrome and hyperandrogenism.J Clin Endocrinol Metab.2oo2.87(8):3977-3983.
[29]Gonzalez F.Thusu K.Abdel-Rahman E.et al.Elevated serum levels of tumor necrosis factor alpha in norm al-weight women with polyeys-tic ovary syndrome.Metabolism.1999.48f4):437-441.
[30]Panidis D.Kcurtis A.Farmakiotis D.et al.Serum adiponeetin levels in women with polycystie ovary syndrome.Hum Reprod,2003,18(9):1790-1796.
[31]Roberts VJ,Barth S,el-Roeiy A,et al.Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome.[J]Clin Endocrinol Metab,1994,79:1434-1439.
[32]Toshihiro F,Yisrael S. Dynamics of inhibin subunit and follistatin mRNA during development of normal and ploycystic ovary syndrome follicles. [J]. Clin Endocrinol Metab,2001,86(9):4206-4151.
[33]Norman RJ,Milner CR,Groome NP,et al. Circμlating follistatin oncentrations are higher and active concertrations are lower in polycystic ovarian syndrome. Hum Reprod,2001,16 (4):668-6721.
[34]徐雯,王元佩,赵采,等.多囊卵巢综合征患者血清、卵泡液中胰岛素样生长因子—Ⅰ水平研究[J].福建医药杂志,2004,26(4)：113.
[35]初永丽,邱红玉,孙永玉.多囊卵巢综合征患者血清肿瘤坏死因子-a的检测及意义[J].实用妇产科杂志,2003,3：167-168.
[36]Diamanti Kandarak is E, BartzisM I, Bergiele A T, et.Microsatellite polymo rph ism (tttta) (n) at-528 base pairs of gene CYP1 la lphauences hyperandro genem ia in patients with polycystic ovary syndrome[J]. ertil S teril,2000,73 (4):735-741.
[37]Gao YQ, Qiao J, Zhang XW, et al. The androgen recep tor CAG repeat polymorphism and polycystic orarvy syndrome [J]. NatlMed J China,2003,83:598-599.
[38]Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleo tide po lymo rph ism at the tyro sine k inase domain of the insμlin receptor gene is associated w ith polycystic ovary syndrome[J]. Fertil S teril,2002,78 (6):1240-1243.
[39]Lindell K, Bennett PA, Itoh Y, et al. L ep tin receptor5'untranslated regions in the rat:relative abundance, genom ic o rganization and relation to putative response elements[J]. M ol Cell E nd ocrinol,2001,172 (1-2):37-45.
[40]谭丽,郑英,朱桂金等.LH-p基因突变与多囊卵巢综合征关系的研究[J].中国实用妇科与产科杂志,2005,21(6)：358-359.
[41]Tong Y, L iaoWX, Roy AC, et al. A ssociation of A cc I polymorphism in the follicle stimμlating hormone bet gene with polycystic ovary syndrome [J]. Fertil S teril,2000,74 (6):1233-1236.
[42]Peral B, San M illan JL, Castello R, et al. Comment:the meth ionine 196 arginine polymorphism in exon 6 of the TN F recep to r2 gene (TN FRSF1B) is associated w ith the polycystic ovary syndrome and hyperandrogenism [J]. J C lin E nd ocrinolM etab, 2002,87 (8):3977-3983.
[43]肖承宗.对多囊卵巢综合征所致不孕的认识与治疗.江苏中医药[J].2006.27(3)：8.
[44]马素侠,梅本华,等.六味地黄丸加味治疗多囊卵巢综合征疗效分析[J].新疆中医药,2000,18(3)：22-23.
[45]罗元恺,郑国平.以补肾为主治疗更年期综合征临床研究[J].中国医药学报,1995,(2)：25.
[46]史莲花,韩宁.楮玉霞教授治疗多囊卵巢综合征的经验[J].四川中医,2004,22(1)：1.
[47]朱红鹏,张龚,等.难治性多囊卵巢综合征的中西结合治疗[J].中国民间疗法,2001,9(8)：9-10.
[48]黎小斌,李丽芸.导痰种子方联合克罗米芬治疗多囊卵巢综合征[J].实用医学杂志,2000,16(4)：330-331.
[49]卢清艺.加味补中益气汤和克罗米芬治疗多囊卵巢综合征[J].河北医科大学学报,2000,21(2)：113.
[50]侯璟玟,俞瑾等.中药天癸方治疗多囊卵巢综合征中高雄激素高胰岛素血症的研究[J].中国中西医结合杂志,2000,20(8)：589-592
[51]陈玲,王丽英.健脾益肾化痰汤治疗多囊卵巢综合征30例[J].江苏中医,1999,20(7)：31.
[52]王佳楣.中西药物对多囊卵巢综合征生殖和代谢功能的影响[J].山东中医药大学学报,2002,26(3)：203.
[53]万朝霞.谈勇教授治疗多囊卵巢综合征的临证经验[J].黑龙江中医药,2003,5：31.
[54]刘瑞芬.以补、调、通三步疗法为主治疗多嶷卵巢综合征[J].江苏中医药,2006,27(3)：10.
[55]夏桂成,用动静观指导滋阴补肾调治多囊卵巢综合征[J].江苏中医药,2006,27(3)：12.
[56]杨悦娅.朱南孙治疗多秦卵巢综合征的思路与方法[J].上海中医药杂志,2006,40(1)：43-44.
[57]Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin through pregnancy in women with polycystic syndrome appears to safely reduce first-trimester spontaneous abortion:a pilot study. Fertil Steril,2001,75:47-51.
[58]Glueck CJ, Wang P, Smith S, et al. Metformin-induced resumption oI normal menses in 39 of 43 (91%)previously amenorrheic women with polycystic ovary syndrome. Metabolism,1999,48:511-519.
[59]Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhihitor aclivily:an independent risk factor for the high miscarrige rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999,48:1589-1595.
[60]Mikola M, Hiilesmaa V, Halttumen M, et al. Obsteric outcome in women with polycystic ovarian syndrome. Hum Repord,2001,16:226-229.
[61]Solomon CG, Carroll JS, Okamura K, et al. Higher cholesterol and insμlin levels in pregnancy are associated with increased risk for for prenancy-induced hypertension. Am J Hypertens,1999,12(3):276-282.
[62]Dale BS, Tanho T, Storeng R, et al. Insμlin resistance and the polycystic ovarian syndrome:recent advances. Gyvnecol Obstel Invest,2002,54(2):94-98.
[63]Talbott E0, Zborowekii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascμlar disease? Review of the evidence.Minerva Ginecol,2004,56 (1):27-39.
[64]]Birdsall MA. Farquhar CM. Polycystic ovaries in pre-and post-menopausal women.Clin Endocrinol,1996,44:89-93.
[65]Robinson S et al. Dyslipidem is is associated with insμlin resistance in women with polycystic ovaries.Clin En-docxinol,1996,44:277.
[66]Guzick DS Talboll E0, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome:initial resμlls from case-control study. Am J Obstet Gynecol,1996,174:1224-1229.
[67]OLeary DH, Polka JF Wolfson SK, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardio Vascμlar Health Study.CHS Collaborative Research Group. Stroke,1991,22:1155-1163.
[68]Festa A, D'Agostino J r R, Howard G, et al. Chronic subclinical in-flammation as part of the insμlin resistance syndrome:the Insμlin Resistance Atherosclerosis Study (IRAS) [J]. Circμlation,102:42-47.
[69]Laure MP, Katriina R, Aimo R, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome[J].Clinical Endocrinology & Metabolism,2003,88 (10):4649-4654.
[70]Wild S, Pierpoint T, McKeigue P, et al. Cardiovascμlar disease in women with polycystic ovary syndrome at long-term follow-up:a retrospective cohort study.Clin Endocrinol,2000,52:595-600.
[71]Norman R J,Masters L,Milner C R,et al.Relative of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndronme[J].Hum Reprod,2001,16:1995-1998.
[72]高劲松,沈铿,郎景和,等.子宫内膜癌患者的临床分析.中华妇产科杂志[J].2004,39(3)：159-161.
[73]Schwimmer J B,Khorram O,Chiu V et al.Abnormal aminotransferase activity in women with polycystic ovarian syndronme[J].Fertil Steril,2005,83(2):498-497.
[74]张丽珠主编.临床生殖内分泌与不孕症.第一版.北京：科学出版社,2001.374-468.
[75]李岩,陶华.妈富隆治疗40例多囊卵巢综合征疗效分析[J].中国计划生育学杂志,2001,70(2)：103.
[76]林琳,刘复权.复方醋酸环丙孕酮治疗多囊卵巢综合征[J].国外医学妇幼保健分册,2003,14(6)：371-372.
[77]刘泽安,薛元明,蔡琼等.二甲双胍对多囊卵巢综合征伴假性黑棘皮病和胰岛素抵抗的作用[J].中国医生杂志,2003,5(3)：353-354.
[78]宋菊香,沈鸿敏,李建业,等.二甲双胍对多囊卵巢综合征患者纤溶系统、内分泌、代谢的影响及对耐氯米芬的作用[J].中华妇产科杂志,2002,37(2)：89.
[79]郑志群,李美芝,林益川,等.罗格列酮对多囊卵巢综合征胰岛素抵抗及高雄激素血症的治疗研究[J].中华妇产科杂志,2002,37(5)271-273.
[80]许志保.中药人工周期疗法的应用[J].江苏中医,1997,18(11)：12.
[81]郝兰枝,魏俊英.中药人工周期治疗青春期多囊卵巢综合征40例[J].中药研究,2003,16(3)：36.
[82]侯璟玟,俞瑾,魏美娟.中药天癸方治疗多囊卵巢综合征高雄激素高胰岛素的研究[J].中国中西医结合杂志,2000,20(8)：589-592.
[83]吕琪,初琦,阴春霞,等.二甲双胍和达因-35联合应用治疗多囊卵巢综合征40例分析[J].中国妇幼保健,2004,19(2)：93.
[84]冯玉昆,陆义芹,孙跃平,等.达英-35联合二甲双胍治疗肥胖型PCOS的临床探讨[J].昆明医学院学报,2005,26(1)：47-50.
[85]张富青,邹芳,崔玉琳,等.二甲双胍联合妈富隆治疗多囊卵巢综合征临床分析[J].中原医刊,2004,31(8)：61.
[86]王婕,张凌,赵丽萍,等.二甲双胍辅助克罗米芬用于多囊卵巢综合征促卵泡发育的疗效观察[J].生殖与避孕,2005,25(2)125-126.
[87]任建民,吕怡静,唐宽晓,等.罗格列酮联合二甲双胍治疗多囊卵巢综合征的临床疗效观察[J].现代妇产科进展,2004,13(3)：197-199.
[88]王洪萍,刘默,王静,等.吡格列酮联合二甲双胍治疗PCOS伴IR疗效观察[J].山东医药,2005,45(25)：56.
[89]郑志群,林益川,马炎辉等.GnRH-a加达因-35治疗多囊卵巢综合征[J].实用妇产科杂志,2001,17(3)：165-166.
[90]袁超燕,陈宏芳.腹腔镜手术配伍药物治疗多囊卵巢综合征性不孕[J].湖北民族学院学报·医学版,2002,19(2)：56.
[91]邵瑞云,郎丰君,蔡金凤,等.补肾活血中药加克罗米芬治疗多囊卵巢综合征所致不孕的临床观察[J].中国中西医结合杂志,2004,24(1)：41-43.
[92]黎小斌,李丽芸.导痰种子方联合克罗米芬治疗多囊卵巢综合征[J].实用医学杂志,2000,16(4)：330-331.
[93]侯丽辉,马丽君,于凤娟,等.性激素监测中西药治疗多囊卵巢综合征16列[J].中医药学报,2000,28(1)：48-49.
[94]陈翔.中西医结合治疗多囊卵巢综合征之不孕38例[J].黑龙江中医药,20003,1：14.
[95]张明敏,黄光英,陆付耳,等.中药联合氯米芬治疗耐氯米芬多囊卵巢综合征的临床研究[J].中华实用中西医杂志,2003,3(16)：157-159.
[96]黎小斌,李丽芸,黄建玲,等.腹腔镜手术辅以补肾化痰中药治疗多囊卵巢综合征[J].新药与临床药理,2002,13(2)：23.
[97]Glued CJ, Papanna R,Wang P1Incidence and treatment of metabolic syndrome in newly refrred women with firmed olycystic ovarian syndrome1Metabolism,2003,52 (7):908-915
[98]Sesti G,Federid M,Lauro D,et all Molecμlar mechanism of insulin resistance in type diabetes mellitus:role of the insμlin receptor variant forms,Diabetes Metab Res ev,2001,17 (5):363-373
[99]高献青,孙宝治.肥胖型与非肥胖型PCOS患者内分泌代谢状态及治疗观察[J].山东医药.2004,44(24)：20-21
[100]丁彩飞,刘丽华,李美芝.肥胖与非肥胖多囊卵巢综合征患者的临床特征[J].中国煤炭工业医学杂志.2002,5(6)：553-554
[101]林金芳,李昕,朱铭伟.多囊卵巢综合征的分型探讨[J].中华妇产科杂志.2006,41(10)：685-685.
[102]乐杰.妇产科学.北京：人民卫生出版社,2005,第6版：344-345.
[103]郑筱萸.中药新药临床研究指导原则.中药新药治疗月经不调的临床研究指导原则[M].北京：中国医药科技出版社,2002：239-241.
[104]张玉珍.中医妇科学.北京：中国中医药出版社,2002,第一版：123-124.
[105]向坤,李云,张丽娟.排卵功能障碍性不孕的机制[J].山东中医杂志,2000,6,19(5)：326-327.
[106]Goren S,Oron Y,Debel N,et al.Rat oocye maturation:role of calcium in hormone action.Mol Cell Endocrinol,1990,72(2):131-138.
[107]秦达念,佘百蓉,佘运初,等.菟丝子黄酮对实验动物及人绒毛组织生殖功能的影响[J].中药新药与临床药理,2000,11(6)：349-351,386-387.
[108]归绥琪,俞瑾,魏美娟等.补肾中药对雄激素致不孕大鼠垂体、卵巢及肾上腺作用的实验研究[J].中国中西医结合杂,1997,17(12)：735-728.
[109]杨宗孟.女宝治疗女子肾虚不孕46例临床观察初步小结[J].长春中医学院学报,1988,4(10)：10.
[110]李炳如,余运初.补肾对下丘脑-垂体-性腺轴功能的影响[J].中医杂志,1984,25(7)：63-64.
[111]张华,冉雪梦,陈芊等.补肾活血方增强子宫内膜降钙素基因表达的临床研究[J].中国计划生育学杂.2007,137(3)：173.
[112]Nestler JE.Insμlin and adrenal androgens. Reproductive Endocrinology,1994,12 (1):1-5.
[113]华等,张巨明,柴松岩,等.肾健脾养血通利法治疗多囊卵巢综合征临床资料分析[J].北京中医杂志,2002,21(6)：323-326.
[114]Gambineri A, Pelusi C, Vicennati V. et al. Obesity an d the polycystic ovary syndrome. Int J Obes Relat Metab Disord,2002,26:883-896.
[115]Glued CJ, Papanna R,Wang P1Incidence and treatment of metabolic syndrome in newly refrred women with confirmed polycystic ovarian syndrome 1 Metabolism,2003,52 (7):908-9151.
[116]Sesti G,Federid M,Lauro D,et all Molecμlar mechanism of insulin resistance in type diabetes mellitus:role of the insμlin receptor variant forms,Diabetes Metab Res Rev,2001,17(5):363-3731.
[117]Poretsky L.Clemons K, Bogovich K Hyperinsμlinemia and homan Chorionic gonadotropin synergistically promote the growth of ovarian follicμlar cysts in rats. Metabolism.1992.41:903-910.
[118]Filicor M, Flamignic c,cognigni G,et al. Increased insμlin secretion in patients with mμltifollicμlar and polycystic ovaries and its impact onovμlation induction.Fertil steril 1994.62:279-285.
[1]程泾.妇科疑难病现代中医诊断与治疗。北京：人民卫生出版社,2003：250。
[2]张丽珠主编。临床生殖内分泌与不孕症。第一版。北京：科学出 版社,2001.374-468。
[3]李岩,陶华。妈富隆治疗40例多囊卵巢综合征疗效分析。中国计划生育学杂志。2001,70(2)：103.
[4]林琳,刘复权。复方醋酸环丙孕酮治疗多囊卵巢综合征。国外医学妇幼保健分册。2003,14(6)：371-372。
[5]刘泽安,薛元明,蔡琼。二甲双胍对多囊卵巢综合征伴假性黑棘皮病和胰岛素抵抗的作用。中国医生杂志。2003,5(3)：353-354。
[6]宋菊香,沈鸿敏,李建业,等。二甲双胍对多囊卵巢综合征患者纤溶系统、内分泌、代谢的影响及对耐氯米芬的作用。中华妇产科杂志。2002,37(2)：89。
[7]郑志群,李美芝,林益川,等。罗格列酮对多囊卵巢综合征胰岛素抵抗及高雄激素血症的治疗研究。中华妇产科杂志。2002,37(5)271-273
[8]张爱荣,徐永萍,傅艺冰,等。腹腔镜电凝打孔治疗多囊卵巢综合征20例临床观察。腹腔镜外科杂志。2001,6(1)：36-37。
[9]王庆一,杨桂艳。腹腔镜多点活检对多囊卵巢综合征的治疗作用。实用医学杂志。2001,17(3)：219-220。
[10]张萍,凌奋,汤蕴琦。腹腔镜单极电针烧灼治疗多囊卵巢综合征。中国现代手术学杂志。2001,5(4)：270-271.
[11]许志保。中药人工周期疗法的应用。江苏中医,1997,18(11)：12。
[12郝兰枝,魏俊英。中药人工周期治疗青春期多囊卵巢综合征40 例。中药研究。2003,16(3)：36。
[13]侯璟玟,俞瑾,魏美娟。中药天癸方治疗多囊卵巢综合征高雄激素高胰岛素的研究。中国中西医结合杂志。2000,20(8)：589-592。
[14]吕琪,初琦,阴春霞等。二甲双胍和达因-35联合应用治疗多囊卵巢综合征40例分析。中国妇幼保健。2004,19(2)：93。
[15]冯玉昆,陆义芹,孙跃平等。达因-35联合二甲双胍治疗肥胖型PCOS的临床探讨。昆明医学院学报,2005,26(1)：47-50。
[16]张富青,邹芳,崔玉琳等。二甲双胍联合妈富隆治疗多囊卵巢综合征临床分析。中原医刊,2004,31(8)：61。
[17]徐爱萍,施蔚虹。克罗米芬联合二甲双胍治疗多囊卵巢综合征疗效观察。齐齐哈尔医学院学报。2003,24(10)：1112。
[18]赵海波,芦小娟,任菊霞等。二甲双胍与克罗米芬联合治疗难治性多囊卵巢综合征。第四军医大学学报。20003,24(6)：560-562。
[19]王婕,张凌,赵丽萍等。二甲双胍辅助克罗米芬用于多囊卵巢综合征促卵泡发育的疗效观察。生殖与避孕。2005,25(2)125-126。
[20]任建民,吕怡静,唐宽晓等。罗格列酮联合二甲双胍治疗多囊卵巢综合征的临床疗效观察。现代妇产科进展,2004,13(3)：197-199。
[21]王洪萍,刘默,王静。吡格列酮联合二甲双胍治疗PCOS伴IR疗效观察。山东医药,2005,45(25)：56
[22]郑志群,林益川,马炎辉等。GnRH-a加达因-35治疗多囊卵巢综 合征。实用妇产科杂志。2001,17(3)：165-166。
[23]袁超燕,陈宏芳。腹腔镜手术配伍药物治疗多囊卵巢综合征性不孕。湖北民族学院学报·医学版。2002,19(2)：56。
[24]邵瑞云,郎丰君,蔡金凤等。补肾活血中药加克罗米芬治疗多囊卵巢综合征所致不孕的临床观察。中国中西医结合杂志,2004,24(1)：41-43。
[25]黎小斌,李丽芸。导痰种子方联合克罗米芬治疗多囊卵巢综合征。实用医学杂志,2000,16(4)：330-331。
[26]侯丽辉,马丽君,于凤娟,等。性激素监测中西药治疗多囊卵巢综合征16列。中医药学报,2000,28(1)：48-49。
[27]陈翔。中西医结合治疗多囊卵巢综合征之不孕38例。黑龙江中
医药。20003,1：14。
[28]张明敏,黄光英,陆付耳,等。中药联合氯米芬治疗耐氯米芬多囊卵巢综合征的临床研究。中华实用中西医杂志。2003,3(16)：157-159。
[29]黎小斌,李丽芸,黄建玲,等。腹腔镜手术辅以补肾化痰中药治疗多囊卵巢综合征。新药与临床药理,2002,13(2)：23。